Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
US Judge Dismisses Gautam Adani Criminal Charges 
3 clinical-grade skincare creams you really shouldn’t buy online 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Eli Lilly has officially entered the elite $1 trillion market-value club, becoming the first pharmaceutical company to reach this milestone. The company’s extraordinary rise is fueled largely by explosive global demand for weight-loss and diabetes treatments, a sector that has rapidly transformed into one of healthcare’s most lucrative markets.
Lilly’s stock has surged more than 35% this year thanks to the success of its blockbuster drug tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for obesity. In a remarkable shift, sales of these medicines have even surpassed Merck’s Keytruda, making tirzepatide the world’s best-selling drug. Mounjaro and Zepbound have also helped Lilly overtake longtime rival Novo Nordisk, which initially dominated the obesity-drug landscape. Novo’s Wegovy faced early supply shortages after its 2021 launch, giving Lilly crucial momentum. Stronger clinical results and faster manufacturing expansion further accelerated Lilly’s lead.
Shares briefly hit an all-time high near $1,051, and the stock now trades at a premium valuation—about 50 times expected earnings—reflecting investor confidence in long-term demand for GLP-1 treatments. Since Zepbound’s late-2023 debut, Lilly’s market performance has far outpaced the broader S&P 500, climbing more than 75%.
In the latest quarter, Lilly reported over $10 billion in combined obesity and diabetes drug revenue, representing more than half of its total $17.6 billion sales. Analysts say the company’s pipeline, pricing agreements with the U.S. government, and major domestic manufacturing investments position Lilly for continued dominance, even if near-term revenue faces pressure.
Wall Street projects the global weight-loss drug market could reach $150 billion by 2030, with Lilly poised to control a large share—especially as investors anticipate approval of its promising oral drug, orforglipron, next year.
Still, analysts caution that sustaining growth will require navigating price pressure, scaling production, and maintaining a strong pipeline. Even so, many now view Lilly as a potential alternative to tech-sector giants, especially as some AI stocks experience volatility.
